Abstract
trials have shown conflicting results. The ACCORD, ADVANCE and VADT studies examined diabetic patients whose treatment was aimed at reducing HbA1c levels to either below 6% (tight control arm) or between 7 and 7.9%. The three studies observed a slight (6–13%) decrease in the incidence of cardiovascular (CV) events in the tight control arm with no statistical significance [4–6]. The ACCORD study was stopped prematurely after 3.5 years due to a 22% excess in overall mortality and a 35% excess in CV mortality in the tight control arm. By contrast, the ADVANCE study showed a 12% reduction in mortality rates in the tight control arm compared with 7% in the other arm, which was not statistically significant. The effect of glycemic control in acute MI has been studied. In the DIGAMI study, diabetic patients who presented with acute MI were treated with either routine or intensive glycemic control. A significant reduction in mortality within 3 years was found in the intensive control group compared with the routine control group, especially in those patients not treated with insulin before hospitalization [7]. The DIGAMI-2, however, showed no
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
